Human Genetic Modification

Human genetic modification is the direct manipulation of the genome using molecular engineering techniques. Recently developed techniques for modifying genes are often called “gene editing.” Genetic modification can be applied in two very different ways: “somatic genetic modification” and “germline genetic modification.”

Somatic genetic modification adds, cuts, or changes the genes in some of the cells of an existing person, typically to alleviate a medical condition. These gene therapy techniques are approaching clinical practice, but only for a few conditions, and at a very high cost.

Germline genetic modification would change the genes in eggs, sperm, or early embryos. Often referred to as “inheritable genetic modification” or “gene editing for reproduction,” these alterations would appear in every cell of the person who developed from that gamete or embryo, and also in all subsequent generations. Germline modification has not been tried in humans, but it would be, by far, the most consequential type of genetic modification. If used for enhancement purposes, it could open the door to a new market-based form of eugenics. Human germline modification has been prohibited by law in more than 40 countries, and by a binding international treaty of the Council of Europe.

Biopolitical Times
[Image by Amaury Laporte via Flickr] For centuries, Western artistic conventions for depicting infants drew heavily on the Christian typology of the Madonna and child. Even popular secular images of babies often featured poses and compositions similar to those gracing many a European church wall. Twentieth century pieces challenging the notion of whiteness as the norm, as shown in Romare Bearden’s
Biopolitical Times
Singapore’s Bioethics Advisory Committee (BAC) recently announced that it is seeking public feedback about the use of mitochondrial replacement techniques (MRTs), also known as nuclear genome transfer or 3-person IVF, to prevent an uncommon form of mitochondrial disease. The announcement accompanied the release of a report on MRTs
Biopolitical Times

In May 2017, Nature Methods published a short, peer-reviewed letter reporting on a study of off-target mutations caused by CRISPR...

Aggregated News

An analyst at Goldman Sachs asked a troubling question this week about gene therapy.

“Is curing patients a sustainable business...